跳至主要内容
临床试验/jRCT1070220052
jRCT1070220052招募中不适用

Living donor liver transplantation for unresectable perihilar cholangiocarcinoma

Taizo Hibi0 个研究点目标入组 20 人开始时间: 待定最近更新:

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
20
主要终点
3-year overall survival

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Single Arm Study
干预模型
Single Assignment
主要目的
Treatment Purpose
盲法
Open(masking Not Used)

入排标准

年龄范围
15age old over 至 70age old not(—)
性别
All

入选标准

  • Unresectable disease but with no extrahepatic metastases and remains progression-free for 3 months or more under neoadjuvant Tx
  • i. Poor hepatic reserve (future liver remnant less than 40%, ICG-R15 10% or more, or ICG-K less than 0.05)
  • ii. Inability to resume portal vein/arterial inflow due to extensive vascular invasion
  • iii. Extensive longitudinal spread along the biliary tree precluding R0 resection
  • iv. Cholangiocarcinoma arising in the setting of PSC with poorly-defined localization
  • Conditions fit for living donor liver transplantation
  • a) Age, 15-69
  • b) ECOG performance status, 0 or 1
  • c) Laboratory data that meet the following:
  • i. Neutrophil: 1,500/microliter or more
  • ii. Platelet: 30,000/microliter or more
  • iii. Hb: 7.5g/dL or more
  • iv. Cr: 1.5mg/dL or more
  • v. New York Heart Association (NYHA) classes I and II
  • vi. Hugh-Jones classes I and II
  • d) Documented informed consent from the participant

排除标准

  • Presence of intra and extrahepatic metastases
  • Presence of Lymph node metastases
  • Malignancies other than perihilar cholangiocarcinoma
  • Presence of uncontrolled infection
  • Adverse events Grade 4 or more (CTCAE v5.0) due to neoadjuvant therapy
  • Other conditions that are clinically unfit for the study

结局指标

主要结局

3-year overall survival

时间窗: 3 years

Overall survival after living donor liver transplantation for unresectable (includes borderline resectable) perihilar cholangiocarcinoma

次要结局

  • Short-term outcomes after living donor liver transplantation (LDLT)

研究者

发起方
Taizo Hibi

相似试验